Study of XB010 in Subjects With Solid Tumors
Key facts
- Where
- Atlanta, Austin, Chicago, Dallas, Fairfax, Houston, Huntersville, Irvine, Los Angeles, Nashville, Oklahoma City, Orlando, St Louis, The Bronx és Washington D.C., Egyesült ÁllamokSee the 16 sites
- Phase
- 1. fázis
Where in Egyesült Államok
- Winship Cancer InstituteAtlanta, Egyesült ÁllamokTaking people
- NEXT AustinAustin, Egyesült ÁllamokTaking people
- University of Chicago Medical CenterChicago, Egyesült ÁllamokTaking people
- Baylor University Medical CenterDallas, Egyesült ÁllamokTaking people
- Inova Schar CancerFairfax, Egyesült ÁllamokTaking people
- NEXT VirginiaFairfax, Egyesült ÁllamokTaking people
- University of Texas - MD Anderson Cancer CenterHouston, Egyesült ÁllamokTaking people
- Carolina Biooncology InstituteHuntersville, Egyesült ÁllamokNo longer taking part
- City of Hope Orange County Lennar Foundation Cancer CenterIrvine, Egyesült ÁllamokTaking people
- UCLA Department of Medicine - Hematology/OncologyLos Angeles, Egyesült ÁllamokTaking people
- SCRI Oncology PartnersNashville, Egyesült ÁllamokTaking people
- Stephenson Cancer CenterOklahoma City, Egyesült ÁllamokTaking people
- Sarah Cannon Research Institute at Florida Cancer SpecialistsOrlando, Egyesült ÁllamokTaking people
- Siteman Cancer CenterSt Louis, Egyesült ÁllamokTaking people
- Montefiore Medical Center- Montefiore Medical ParkThe Bronx, Egyesült ÁllamokTaking people
- Georgetown University Medical CenterWashington D.C., Egyesült ÁllamokNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Exelixis
- Trial code
- NCT06545331
- Record updated
- 2026. október 30.
- Original description
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.Read full original descriptionShow less
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Age 18 years or older on the day of consent; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; Adequate organ and marrow function; Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent; The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer); Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.